CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis

Company Overview

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive forms of brain cancer. The company’s primary research is centered on addressing glioblastoma multiforme (GBM), an aggressive and often treatment-resistant tumor of the central nervous system. CNS Pharmaceuticals applies a targeted drug-delivery platform designed to enhance blood–brain barrier penetration, enabling higher concentrations of anti-cancer agents to reach tumor sites while aiming to minimize systemic toxicity.

The company’s lead product candidate, berubicin, is a proprietary anthracycline derivative engineered to overcome the limitations of traditional chemotherapy in brain cancers. Berubicin has received orphan drug designation from regulatory authorities in both the United States and Europe for the treatment of glioblastoma. In addition to its lead program, CNS Pharmaceuticals maintains a preclinical pipeline exploring novel small molecules and drug conjugates aimed at expanding treatment options for central nervous system malignancies. Preclinical studies leverage advanced in vitro and in vivo models to optimize compound activity and evaluate potential biomarkers for clinical development.

Founded in 2006 and headquartered in Houston, Texas, CNS Pharmaceuticals collaborates with academic research centers and contract research organizations across North America and Europe. The company actively engages in investigator-sponsored trials and partnerships designed to accelerate development timelines and broaden access to its therapies. It has built a leadership team with extensive experience in oncology drug development, regulatory affairs, and corporate strategy. Key executives include CEO and Chairman Dr. Fred Eshelman, President and Chief Operating Officer Dr. Mahesh Samant, and Chief Financial Officer Christopher J. Ashwa.

With multiple clinical milestones anticipated in the coming years, CNS Pharmaceuticals aims to address a critical unmet need in neuro-oncology. By focusing on molecular innovation and strategic alliances, the company seeks to advance its pipeline while maintaining rigorous safety and efficacy standards. Its mission is to improve outcomes for patients facing the most challenging brain cancers through the development of next-generation therapeutics.

Key Stats

• Today's Range: $0.86 to $0.92
• 50-Day Range: $0.76 to $1.36
• 52-Week Range: $0.73 to $62.00
• Volume: 203,050 shs
• Average Volume: 701,305 shs
• Market Capitalization: $4.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Moderate Buy

CNS Pharmaceuticals Stock Analysis - MarketRank™

CNS Pharmaceuticals scored higher than 43% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

CNS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

CNS Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of CNS Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of CNS Pharmaceuticals is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

CNS Pharmaceuticals has a P/B Ratio of 0.16. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

7.37% of the float of CNS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNS Pharmaceuticals has recently decreased by 13.42%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

CNS Pharmaceuticals does not currently pay a dividend.

Dividend Growth

CNS Pharmaceuticals does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

7.37% of the float of CNS Pharmaceuticals has been sold short.

Short Interest Ratio / Days to Cover

CNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in CNS Pharmaceuticals has recently decreased by 13.42%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.0 / 5
• News Sentiment: 0.62

News Sentiment

CNS Pharmaceuticals has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for CNS Pharmaceuticals this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 0.07% of the stock of CNS Pharmaceuticals is held by insiders.

Percentage Held by Institutions

Only 14.02% of the stock of CNS Pharmaceuticals is held by institutions.

CNSP Stock Analysis - Frequently Asked Questions

How have CNSP shares performed this year?

CNS Pharmaceuticals' stock was trading at $6.02 at the beginning of the year. Since then, CNSP shares have decreased by 85.5% and is now trading at $0.8748.

How were CNS Pharmaceuticals' earnings last quarter?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) issued its quarterly earnings results on Thursday, May, 15th. The company reported ($1.58) EPS for the quarter.

When did CNS Pharmaceuticals' stock split?

CNS Pharmaceuticals's stock reverse split on Friday, February 21st 2025.The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

When did CNS Pharmaceuticals IPO?

CNS Pharmaceuticals (CNSP) raised $9 million in an initial public offering on Friday, November 8th 2019. The company issued 2,100,000 shares at a price of $4.00-$5.00 per share. Benchmark served as the underwriter for the IPO.

How do I buy shares of CNS Pharmaceuticals?

Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of CNS Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 5/15/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:CNSP
• CIK: 1729427
• Web: www.cnspharma.com
• Phone: 800-946-9185
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for CNS Pharmaceuticals: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +2,757.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.50
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3,748.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$14.86 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -385.41%
• Return on Assets: -193.20%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.94
• Quick Ratio: 4.94

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $5.37 per share
• Price / Book: 0.16

Miscellaneous

• Outstanding Shares: 5,460,000
• Free Float: 5,458,000
• Market Cap: $4.78 million
• Optionable: Not Optionable
• Beta: 2.58